The need for economic evaluation in osteoarthritis

Aging Health

Volumn 5, Issue 5, 2009, Pages 591-594

  Bruyère, Olivier ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE SULFATE; HYALURONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

AGING; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EDITORIAL; EXERCISE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HIP OSTEOARTHRITIS; HUMAN; JOINT PROSTHESIS; KNEE OSTEOARTHRITIS; OSTEOARTHRITIS; OSTEOTOMY; PATIENT EDUCATION; PHYSIOTHERAPY; QUALITY ADJUSTED LIFE YEAR; SLOW DRUG RELEASE; STOMACH DISEASE; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 70450182098     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.09.57     Document Type: Editorial

References (37)

1. Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349(9063), 1436-1442 (1997).
2. Reginster JY: The prevalence and burden of arthritis. Rheumatology (Oxford) 41(Suppl. 1), 3-6 (2002).
3. Rabenda V, Manette C, Lemmens R et al.: Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin. Exp. Res. 19(1), 55-60 (2007). (Pubitemid 46534222)
4. Bruyere O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY: Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet. Disord. 9, 165 (2008).
5. Zhang W, Moskowitz RW, Nuki G et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16(2), 137-162 (2008). (Pubitemid 351222155)
6. Jordan KM, Arden NK, Doherty M et al.: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. 62(12), 1145-1155 (2003).
7. Rabenda V, Manette C, Lemmens R et al.: Direct and indirect costs attributable to osteoarthritis in active subjects. J. Rheumatol. 33(6), 1152-1158 (2006). (Pubitemid 43825470)
8. Rabenda V, Burlet N, Belaiche J et al.: Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care. Osteoarthritis Cartilage 14(7), 625-630 (2006). (Pubitemid 43842728)
9. Moore R, Phillips C: Cost of NSAID adverse effects to the UK National Health Service. J. Med. Econ. 2, 45-55 (19990.
10. Andrews G, Simonella L, Lapsley H, Sanderson K, March L: Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis. J. Rheumatol. 33(4), 671-680 (2006).
11. Johannesson M, O'Conor RM: Cost-utility analysis from a societal perspective. Health Policy 39(3), 241-253 (1997). • Outlines how to use cost-utility analysis from a societal perspective and the arguments that could be made for using data, such as a model for economic evaluation of healthcare.
12. Thomas KS, Miller P, Doherty M et al.: Cost effectiveness of a two-year home exercise program for the treatment of knee pain. Arthritis Rheum. 53(3), 388-394 (2005). (Pubitemid 40799878)
13. Mazieres B, Bard H, Ligier M, Bru I, d'Orsay GG, Le Pen C: Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study. Joint Bone Spine 74(5), 453-460 (2007). (Pubitemid 47588986)
14. Pope JE, Prashker M, Anderson J: The efficacy and cost effectiveness of N of 1 studies with diclofenac compared with standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. J. Rheumatol. 31(1), 140-149 (2004). (Pubitemid 38067536)
15. Russo P, Capone A, Attanasio E et al.: Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice. Rheumatology (Oxford) 42(7), 879-887 (2003). (Pubitemid 37220938)
16. Castelnuovo E, Cross P, Mt-Isa S, Spencer A, Underwood M: Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain; the TOIB study [ISRCTN: 79353052]. Rheumatology (Oxford) 47(7), 1077-1081 (2008). (Pubitemid 351865938)
17. Coupe VM, Veenhof C, van Tulder MW et al.: The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee. Ann. Rheum. Dis. 66(2), 215-221 (2007). (Pubitemid 46226057)
18. Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA: Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Pharmacoeconomics 19(10), 1039-1049 (2001).
19. Contreras-Hernandez I, Mould-Quevedo JF et al.: Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs cyclooxygenase-2 selective inhibitors. Cost Eff. Resour. Alloc. 6, 21 (2008).
20. Koskinen E, Eskelinen A, Paavolainen P, Pulkkinen P, Remes V: Comparison of survival and cost-effectiveness between unicondylar arthroplasty and total knee arthroplasty in patients with primary osteoarthritis: a follow-up study of 50,493 knee replacements from the Finnish Arthroplasty Register. Acta Orthop. 79(4), 499-507 (2008).
21. Soohoo NF, Sharifi H, Kominski G, Lieberman JR: Cost-effectiveness analysis of unicompartmental knee arthroplasty as an alternative to total knee arthroplasty for unicompartmental osteoarthritis. J. Bone Joint Surg. Am. 88(9), 1975-1982 (2006).
22. Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S: Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 22(10), 643-660 (2004). (Pubitemid 38951785)
23. Tavakoli M: Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam. Pharmacoeconomics 21(6), 443-454 (2003).
24. Al MJ, Maniadakis N, Grijseels EW, Janssen M: Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Value Health 11(4), 589-599 (2008). (Pubitemid 352036652)
25. Loyd M, Rublee D, Jacobs P: An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol. 7, 25 (2007). (Pubitemid 47162168)
26. Kamath CC, Kremers HM, Vanness DJ et al.: The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 6(2), 144-157 (2003).
27. Ruchlin HS, Insinga RP: A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation. Pharmacoeconomics 26(11), 925-935 (2008).
28. Marshall D, Pericak D, Grootendorst P et al.: Validation of a prediction model to estimate health utilities index Mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the hip. Value Health 11(3), 470-477 (2008). (Pubitemid 351712972)
29. Grootendorst P, Marshall D, Pericak D, Bellamy N, Feeny D, Torrance GW: a model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. J. Rheumatol. 34(3), 534-542 (2007). •• Relates to the development of a formula to translate Western Ontario and McMaster University Osteoarthritis Index scores, collected in clinical trials of patients with osteoarthritis, into Health Utilities Index Mark 3 utility scores for application in economic evaluation. (Pubitemid 46364008)
30. Barton GR, Sach TH, Jenkinson C, Avery AJ, Doherty M, Muir KR: Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual. Life Outcomes 6, 51 (2008).
31. Black WC: The CE plane: a graphic representation of cost-effectiveness. Med. Decis. Making 10(3), 212-214 (1990).
32. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG: Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making 20(3), 332-342 (2000). • Determines the value of a quality-adjusted life year as implied by the value-of-life literature and compares this value with arbitrary thresholds for cost-effectiveness that have come into common use.
33. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146(4), 473-481 (1992).
34. Byrne MM, O'Malley K, Suarez-Almazor ME: Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med. Decis. Making 25(6), 655-666 (2005). (Pubitemid 41667134)
35. Bruyere O, Reginster JY: Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 24(7), 573-580 (2007). (Pubitemid 47195676)
36. Cicuttini FM, Jones G, Forbes A, Wluka AE: Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann. Rheum. Dis. 63(9), 1124-1127 (2004). (Pubitemid 39120365)
37. Bruyere O, Richy F, Reginster JY: Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Ann. Rheum. Dis. 64(12), 1727-1730 (2005). (Pubitemid 41667146)